Nuclear osteopontin-c is a prognostic breast cancer marker

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 729-738

  Zduniak, K ^a   Ziolkowski, P ^a   Ahlin, C ^b   Agrawal, A ^a   Agrawal, S ^a   Blomqvist, C ^c   Fjallskog M L ^c   Weber, G F ^d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

biomarker; breast cancer; cancer progression; immunohistochemistry; prognosis; tissue array

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NUCLEAR OSTEOPONTIN C; OSTEOPONTIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; STAINING; TUMOR GROWTH; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE CONTROL STUDY; CELL NUCLEUS; EARLY DIAGNOSIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; POLAND; PROGNOSIS; SURVIVOR; SWEDEN;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CELL NUCLEUS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OSTEOPONTIN; POLAND; PROGNOSIS; SURVIVORS; SWEDEN;

EID: 84923632548     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.664     Document Type: Article

References (28)

1. Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirström K, Blomqvist C, Amini RM, Fjällskog ML. (2009). Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18: 2501-2506
2. Akaike H. (1974). A new look at the statistical model identification. System identification and time-series analysis. IEEE Trans Automat Contr AC-19: 716-723
3. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Janssen M, Zawaideh S, Rittling S, Denhardt DT, Glimcher MJ, Cantor H. (2000). Eta-1 (Osteopontin): An early component of type 1 (cell-mediated) immunity. Science 287: 860-864
4. Craig AM, Denhardt DT. (1991). The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by oestrogen and progesterone. Gene 100: 163-171
5. Dabbs DJ. (2010). Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3rd edn. Philadelphia: Saunders Elsevier, pp 801-802
6. Firth D. (1993). Bias reduction of maximum likelihood estimates. Biometrika 80: 27-38
7. Hartung F, Weber GF. (2013). RNA Blood levels of osteopontin splice variants are cancer markers. SpringerPlus 2: 110
8. He B, Mirza M, Weber GF. (2006). An osteopontin splice variant induces anchorage independence in human breast cancer. Oncogene 25: 2192-2202
9. Junaid A, Moon MC, Harding GE, Zahradka P. (2007). Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292: C919-C926
10. Kim YW, Park YK, Lee J, Ko SW, Yang MH. (1998). Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13: 652-657
11. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. (2008). Osteopontin-c is a selective marker for breast cancer. Int J Cancer 122: 889-897
12. Niméus-Malmström E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, Amini RM, Jirström K,Wärnberg F, Blomqvist C, Fernö M, Fjällskog ML. (2010). Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer 127: 961-967
13. Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E, Peiró G. (2014). Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol 45: 504-512
14. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L. (2013). Prognostic values of osteopontin-c, E-cadherin and b-catenin in breast cancer. Cancer Epidemiol 37: 985-992
15. Patani N, Jiang W, Mokbel K (2008a) Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer 122: 2646
16. Patani N, Jouhra F, Jiang W, Mokbel K (2008b) Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 28: 4105-4110
17. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427
18. Senger DR, Peruzzi CA, Papadopulous A, Tenen DG. (1989). Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 996: 43-48
19. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz W, Weber GF, Yeo CJ, Arafat HA. (2009). Expression of a prometastatic splice variant of Osteopontin, OPNc, in human pancreatic ductal adenocarcinoma. Surgery 146: 232-240
20. Sullivan J, Blair L, Alnajar A, Aziz T, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. (2011). Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol 26: 893-904
21. Tilli TM, Franco VF, Robbs BK, Wanderley JL, Silva F, Duarte De Mello K, Viola JPB, Weber GF, Gimba ERP. (2011). Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9: 280-293
22. Tilli TM, Thuler LCS, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER. (2012). Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 92: 13-19
23. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508
24. Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J. (2008). Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 38: 438-446
25. Weber GF, Lett S, Haubein N. (2010). Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869
26. Weber GF, Lett GS, Haubein NC. (2011). Meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 25: 433-441
27. Weber GF. (2011). The cancer biomarker Osteopontin: combination with other markers. Cancer Genomics Proteomics 8: 263-288
28. Zhang M-X, Xu Y-J, Zhu M-C, Yan F. (2013). Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma. Asian Pac J Cancer Prev 14: 7315-7319